Granules India Limited (GRANULES) — Announcement
Granules India disclosed that India Ratings & Research confirmed no deviation from the stated utilization of proceeds from its INR 1,762.50 crore preferential issue, with funds deployed across business operations and convertible warrants. The monitoring report validated that 300 crores were used for term loan prepayment in a subsidiary, while 1,462.50 crores remained allocated to other purposes including working capital and vendor payments. No material delays or changes were noted, and the company confirmed adherence to all regulatory requirements.
About Granules India Limited (GRANULES)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when GRANULES files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track GRANULES — Free💡 Ask AI about this filing
📊 More GRANULES filings
- Announcement — 6 July 2026 Granules India announced it secured sole First-to-File status for its ANDA for Sodium Oxybate Extend...
- Announcement — 15 June 2026 Granules India announced its tentative schedule for analyst and investor meetings in London on June ...
- Announcement — 3 June 2026 Granules India announced its US subsidiary Granules Pharmaceuticals received a USFDA Establishment I...
- Announcement — 28 May 2026 Granules India announced a tentative analyst and investor meeting scheduled for June 3, 2026, in Hyd...
- 🔴 Financial Results — 5 May 2026 Granules India reported FY26 revenue of **₹53,656 crores**, up 20% YoY, driven by complex generics a...
🔥 Also filed on 21 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when GRANULES files new disclosures
Track GRANULES filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GRANULES — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research